Lilly’s Mounjaro and Zepbound, weekly injectable drugs targeting GIP and GLP-1, lead in the obesity and diabetes market with over $6 billion in sales. To maintain its position, Lilly is developing new injectables and oral options. Despite progress, competition from less frequent dosing therapies poses a challenge.
Read more from biospace.com
